nShift: Logistics Costs Risk Cutting Into Black-Friday Profits as Carrier Rates Soar by 25%
3.12.2024 12:56:00 CET | Business Wire | Press Release
Sharp increases in delivery costs, by as much as 25%1, may have led to reduced Black-Friday profits for ecommerce businesses. nShift, the global leader in multi-carrier delivery management, is encouraging businesses to start preparing now for next year in order to protect 2025 peak-season profits.
Due to limited capacity across the supply chain, almost a third of businesses (32%) had to deal with a cost hike.2 While it’s still too early to assess the specifics of cost rises on last week’s shopping bonanza, many retailers and warehouses saw carrier rates soar by 25% in 2023. Last year, the average per-item delivery expense in the UK rose from £3.50 to £4.37.3 Other European markets experienced similar increases.
At the same time as businesses are struggling with costs, customers are demanding greater choice over delivery times and shipment options. Research shows that 72% of customers believe that a choice of delivery options is important when shopping with a brand, vendor or retailer for the first time.4
“Black Friday is all about providing the best deal possible. So when carrier costs ramp up over peak season, retailers and warehouses are reluctant to pass on the increase to customers,” says Mattias Gredenhag, CTO at nShift. “The business tends to absorb the cost, cutting into potential peak-season profit.
“Creating capacity is the key to retaining revenue and providing better customer choice. Access to a larger carrier network can reduce warehouses’ exposure to cost increases, enabling them to find cost-effective alternatives more easily. While it is too late to make major infrastructure changes for 2024, retailers and warehouses should start investing now, to ensure they can achieve peak profit in 2025.”
Mattias has released a list of four tips to get businesses planning for 2025:
- Invest in multi-carrier capacity – when demand rises, warehouses have to ensure they have capacity to meet it. This involves having access to the largest network of carriers. Not only does this allow them to scale up, it also enables retailers to offer a greater range of delivery options
- Automatically select the cheapest carrier for each delivery – the right delivery management software enables businesses to automate the carrier booking process, instantly selecting the most cost effective
- Display options and information clearly at checkout – if shoppers want a specific delivery option, make sure they can find it quickly. If next-day delivery is no longer possible because of capacity, reflect this at checkout to avoid confusion. Many consumers seek sustainable shipping and will click away if they can’t find a lower-emissions option
- Communicate, communicate, communicate – if delays have to happen, it’s crucial that retailers communicate this to their customers. In 2025 this can’t just be email – communications need to go to the mobile and social apps that shoppers live their digital lives through. Done well, such messages also create the opportunity for further product promotions
The nShift suite of solutions combines the best aspects of delivery management with customer-facing applications. Our carrier network consists of over 1000 carriers, enabling retailers, vendors and warehouses to operate an end-to-end delivery process from checkout to returns.
About nShift:
nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.
1https://supplychaindigital.com/logistics/black-friday-shipping-costs
2https://supplychaindigital.com/logistics/black-friday-shipping-costs
3https://supplychaindigital.com/logistics/black-friday-shipping-costs
4https://nshift.com/retail-week-shopper-unlocked
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203116351/en/
Contacts
James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom